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Objectives: Pyrrolobenzodiazepine (PBD) dimers, tethered through inert propyldioxy or pentyldioxy linkers,
possess potent bactericidal activity against a range of Gram-positive bacteria by virtue of their capacity to
cross-link duplex DNA in sequence-selective fashion. Here we attempt to improve the antibacterial activity
and cytotoxicity profile of PBD-containing conjugates by extension of dimer linkers and replacement of one
PBD unit with phenyl-substituted or benzo-fused heterocycles that facilitate non-covalent interactions with
duplex DNA.
Methods: DNase I footprinting was used to identify high-affinity DNA binding sites. A staphylococcal gene
microarray was used to assess epidemic methicillin-resistant Staphylococcus aureus 16 phenotypes induced
by PBD conjugates. Molecular dynamics simulations were employed to investigate the accommodation of com-
pounds within the DNA helix.
Results: Increasing the length of the linker in PBD dimers led to a progressive reduction in antibacterial activity,
but not in their cytotoxic capacity. Complex patterns of DNA binding were noted for extended PBD dimers.
Modelling of DNA strand cross-linking by PBD dimers indicated distortion of the helix. A majority (26 of 43)
of PBD-biaryl conjugates possessed potent antibacterial activity with little or no helical distortion and a
more favourable cytotoxicity profile. Bactericidal activity of PBD-biaryl conjugates was determined by inability
to excise covalently bound drug molecules from bacterial duplex DNA.
Conclusions: PBD-biaryl conjugates have a superior antibacterial profile compared with PBD dimers such as
ELB-21. We have identified six PBD-biaryl conjugates as potential drug development candidates.
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Introduction
The large majority of antibiotics in current clinical use are derived
from bactericidal or bacteriostatic molecules produced as sec-
ondary metabolites by microbes, predominantly those belonging
to the moulds and actinobacteria.1 Some of the most potent and
least toxic compounds from the initial wave of antibacterial drug
discovery target cellular structures such as peptidoglycan, unique
to bacteria, or selectively interfere with the protein synthesizing
machinery of prokaryotes over host cell processes. Such screening
identified molecules such as the pyrrolobenzodiazepines (PBDs)
tomaymycin, anthramycin and DC-81, which exerted potent
antibacterial activity against human pathogens through a cap-
acity to bind to DNA;2–4 some of these compounds have potential
as cancer chemotherapeutics, but a high degree of cytotoxicity
has rendered them unattractive as antibacterial antibiotics in
comparison with other classes of compound. However, the evolu-
tion of multidrug-resistant pathogens capable of a rapid and ef-
ficient horizontal transmission of genes encoding antibiotic
resistance determinants has facilitated the erosion of much of
the therapeutic value of front-line antibacterial chemotherapeu-
tic agents in a relatively short time frame.5,6 Increasing multidrug
resistance in Gram-negative pathogens such as Pseudomonas
aeruginosa and Acinetobacter baumannii has forced the
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reappraisal of colistin for systemic use; this polymyxin antibiotic,
discovered .50 years ago and until recently considered too
toxic for non-topical use, is now widely used systemically due
to the limited therapeutic options available for these infections.7
We have taken our cues from this trend and are evaluating the
antibacterial potential of novel chemotherapeutics of the PBD
class of DNA-interactive agents.8–10
PBDs exert their biological activity through covalent binding via
their N10-C11 imine/carbinolamine moieties to the C2-amino
position of a guanine residue within the minor groove of DNA
(Figure 1); monomers span three DNA base pairs with a prefer-
ence for Pu-G-Pu (where Pu¼purine and G¼guanine; reactive
guanine emboldened) sequences and block transcription by the
inhibition of RNA polymerase.11 The potency, binding affinity
and sequence specificity of PBDs can be enhanced by tethering
two PBD units through an inert propyldioxy [-O-(CH2)3-O-
diether] or pentyldioxy [-O-(CH2)5-O- diether] linker via their C8/
C8′ positions to form dimers that are able to cross-link appropri-
ately separated guanines on opposing DNA strands.12 Such linkers
facilitate non-covalent interactions with adjacent adenine
residues that determine a preference for A:T-rich sequences.
For example, a [-O-(CH2)3-O- diether] linker, such as that incorpo-
rated into the structure of SJG-136 (Figure 1), engenders binding
predominantly to embedded 5′-Pu-GATC-Py sequences;12,13
extending this linker region to n¼5 enables dimers such as
ELB-21 (Figure 1) to span an extra base pair and cross-link
sequences such as 5′-Pu-GATTC-Py and 5′-Pu-GAATC-Py.12 Both
three- and five-carbon-linked dimers show strong bactericidal
activity against a range of Gram-positive pathogens,8,14 but no
activity against Gram-negative bacteria due to the barrier func-
tion of the outer membrane.8 Of the compounds shown in
Figure 1, ELB-21 was significantly more potent than either
SJG-136 or DRG-16 and was found to activate resident pro-
phages, up-regulate genes within pathogenicity islands and
invoke a RecA-LexA-mediated DNA damage response.10,14 PBD
dimers are relatively toxic molecules, as evidenced by compari-
son of in vitro cytotoxicity against tumour and non-tumour cell
lines;15,16 recent evidence has emerged that dimers form
sequence-dependent intrastrand and monoalkylated adducts in
addition to a variety of interstrand cross-links,14,17 and such mul-
tiple binding patterns contribute to their cytotoxicity profiles.
The G+C content of DNA from Staphylococcus spp. and
Streptococcus spp. is relatively low—30%–38% and 33%–44%,
respectively18—consequently, it may be possible to decrease
the cytotoxicity of PBDs by restricting non-covalent interactions
with A:T-rich regions. We have taken two approaches towards
the design of PBD-based conjugates with the capacity to recog-
nize and bind selectively to A:T- and G:C-containing sequences in
the DNA of Gram-positive pathogens. In the first instance, we
synthesized PBD dimers containing a number of joined hetero-
cyclic building blocks between the PBD units rather than the
simple methylene chains utilized in the synthesis of SJG-136,
DRG-16 and ELB-21. Thus, the linked heterocyclic units extend
the length of the base pairs spanned between the interstrand
cross-linked guanines; the heterocyclic building blocks selected
are rich in hydrogen bond donating and accepting capability,
allowing the potential for the recognition of specific DNA
bases spanned by the linker. Secondly, we have designed
and synthesized a series of PBD-biaryl conjugates in which
poly(N-methylpyrrole) units have been attached to the C8 pos-
ition of PBD units by a four-carbon linker;19 poly(N-methylpyrrole)
units such as 4-(1-methyl-1H-pyrrol-3-yl)benzenamine (MPB)
interact in a non-covalent manner with DNA and have a strong
preference for G:C tracts. Thus, PBD-MPBs and other PBD-biaryl
conjugates are DNA monoalkylating agents with G:C recognition
properties and exert cytotoxic effects against human tumour cell
lines whilst sparing non-tumour cell lines such as the fibroblast
line WI38. We have therefore evaluated the antibacterial proper-
ties of members of these DNA mono- and dialkylating libraries
against Gram-positive pathogens in relation to their cytotoxicity
and, where appropriate, their DNA-binding profiles.
Materials and methods
Bacteria and cell lines
Epidemic methicillin-resistant Staphylococcus aureus (EMRSA) strains
EMRSA-15 and EMRSA-16 were isolated from clinical material at the
Royal Free Hospital, London;20 MRSA strain BB568 was a gift from Brigitte
Berger-Ba¨chi, Institute of Medical Microbiology, University of Zu¨rich,
Switzerland. The community-associated MRSA isolate USA300 was
purchased from the ATCC as BAA-1556. Vancomycin-intermediate
S. aureus (‘VISA’) strain Mu50 is an MRSA clinical isolate with intermediate
vancomycin resistance, and was isolated and provided by Keiichi Hira-
matsu, Juntendo University, Tokyo. ATCC 29213 is an antibiotic-
susceptible S. aureus reference strain. The vancomycin-resistant entero-
cocci (VRE) Enterococcus faecalis VRE1 and Enterococcus faecium
VRE10 were isolated at the Royal Free Hospital. Bacteria were grown in
Mueller–Hinton (MH) broth (Oxoid) or on MH agar plates at 378C. The
MICs of antibacterial agents were determined by the CLSI broth micro-
plate assay as previously described;9 agents were dissolved in DMSO
prior to dilution in broth. At the concentrations used, the solvent had
no effect on bacterial growth. Three MIC determinations per strain
were performed in duplicate for each compound tested.
For cytotoxicity evaluation, the human lung fibroblast cell line WI38
and ovarian (A2780) and breast (MCF7) human cancer cell lines were
employed. The cells were grown at 378C in a 5% CO2 humidified atmos-
phere, either in Dulbecco’s modified Eagle’s medium or modified Eagle’s
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Figure 1. Mechanism of PBD binding to the N2 of guanine in the DNA minor groove, and structure of the PBD dimers SJG-136, DRG-16 and ELB-21.
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medium (depending on the cell line) supplemented with 10% (v/v) fetal
bovine serum (Biosera), 1% (w/v) L-glutamine, 1% (w/v) non-essential
amino acids and 0.05% (w/v) hydrocortisone (Invitrogen). Cells were
seeded into 96-well plates (total volume 100 mL) and allowed to reach
a 30%–40% degree of confluence before the addition of compounds dis-
solved in sterilized ultrapure water up to a concentration of 100 mg/L.
Serial decimal dilutions were employed and 25 mL aliquots added to
cells. After 24 h of continuous drug exposure, cells were washed with
PBS and placed in 200 mL of drug-free medium for 72 h after the end
of drug exposure. The cytotoxicity was determined spectrophotometric-
ally at l¼570 nm using the MTT colorimetric assay.21 IC50 values were
calculated by dose–response analysis using OriginLab 6.0w software
(Silverdale Scientific Ltd, Stoke Mandeville, UK).
PBD dimers
Thirteen PBD dimers were examined in this study and structural data for
these compounds are shown in Table 1. These include the C2-phenyl (A2)
and C2-thiophenyl (A1) derivatives of ELB-21, and symmetric (e.g.
SG-2860) and asymmetric (SG-2891) tri-, tetra-, penta- and hexapyrrole
dimers containing DNA-interactive heterocyclic units separating the two
PBD moieties. ELB-21 was obtained from Spirogen Ltd (London, UK)
and was synthesized as described previously.22 As previous studies of
the structure–activity relationships of PBD monomers have demon-
strated an improvement in activity when C2/C3 endo-unsaturation is
combined with an aryl (or planar) substituent at C2,23,24 we functiona-
lized each PBD unit C-ring24 of ELB-21 to yield compounds A1 and A2.
The asymmetric C8/C8′-tripyrrole-linked PBD dimer SG-2860, with the
capacity to form high-affinity cross-links spanning 11 bp, was synthe-
sized according to Tiberghien et al.25 In this molecule the PBD units are
tethered through a pyrrole-imidazole-pyrrole (py-Im-py) linker. SG-2891
is a C11-bisulphite-modified, highly water soluble prodrug of SG-2860
with a decreased rate of DNA adduct formation in comparison with
SG-2860 and was modified according to published procedures.26,27
In SG-2910, the DNA cross-linking span has been further extended by
including a b-alanine (Ala) residue in the Im-py-Ala-Im-py linker.
SG-2242 and the C11-bisulphite-modified derivative SG-2243 were
designed to span 13 DNA base pairs by virtue of a py-py-alk-py-py
linker (alk; alkyl chain); SG-2907 was prepared utilizing a py-Im-alk-Im-py
tether. A further chain extension was introduced through a py-py-
Im-alk-Im-py-py linker (SG-2904 and SG-2906). SG-2087 and SG-2088
are 1-methyl-1H-pyrrole-2,4-dicarboxylic acid bis-[(11aS)(7-methoxy-5-
oxo-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-8-yl)-amide]
and 1-methyl-1H-pyrrole-2,5-dicarboxylic acid bis-[(11aS)(7-methoxy-5-
oxo-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-8-yl)-
amide], respectively. Further details of the synthesis of these molecules
can be found in patent applications WO 2000/012508, WO 2005/
085260, WO 2005/085251, WO 2005/085250, WO 2005/085177, WO
2007/039752, WO 2007/039752 and WO 2009/060215.
PBD-biaryl conjugates
A library of 43 PBD-biaryl conjugates was employed; their structures and
key chemical data are shown in Table S1 (available as Supplementary
data at JAC Online). The conjugates incorporate members of a set of
biaryl building blocks, shown in Table S2 (available as Supplementary
data at JAC Online), that are based on phenyl-substituted heterocycles
sufficiently long to span two DNA base pairs and facilitate a switch of
binding preference from A:T-rich to G:C-rich sequences.
DNase I footprinting
DNase I footprinting with the PBD dimers was performed as previously
described28 using the HexA and HexB DNA fragments. The sequences
of these fragments are shown in Figure S1 (available as Supplementary
data at JAC Online). These synthetic cloned fragments were designed
so that between them they contain all 64 symmetrical hexanucleotide
sequences. In order to facilitate examination of the binding sites that
are located at either end of these sequences, each fragment was
cloned in both orientations (HexAfor with HexArev and HexBfor with
HexBrev) as previously described.29 These footprinting templates were
considered to be especially useful for testing these symmetrical
ligands, rather than natural restriction fragments that contain a
random mixture of potential binding sites. Radiolabelled DNA fragments
were obtained by digesting the parent plasmids with HindIII and SacI
(HexA) or EcoR1 and Pst1 (HexB), and labelled at the 3′-end of the
EcoR1 or HindIII sites with a-[32P]dATP using reverse transcriptase. The
radiolabelled fragments of interest were separated from the remainder
of the plasmid DNA on 6% (w/v) polyacrylamide gels. The DNA was
eluted and dissolved in 10 mM Tris-HCl, pH 7.5, containing 0.1 mM
EDTA to give 10 cps/mL, as determined on a hand-held Geiger counter
(,10 nM). Ligand–DNA complexes were prepared by mixing 1.5 mL of
DNA with 1.5 mL of ligand (diluted in 10 mM Tris-HCl, pH 7.5, containing
10 mM NaCl) to give final ligand concentrations of 3, 1, 0.3 and 0.1 mM.
These mixtures were incubated overnight at 208C before digesting with
2 mL of DNase I (0.01 U/mL, diluted in 20 mM NaCl/2 mM MgCl2/2 mM
MnCl2). The reaction was stopped after 1 min by adding 4.5 mL of
formamide containing 10 mM EDTA and bromophenol blue. Samples
were then boiled for 3 min before loading onto an 8% (w/v) denaturing
polyacrylamide gel (40 cm) containing 8 M urea. Gels were fixed in 10%
(v/v) acetic acid, dried under vacuum and subjected to autoradiography
using a phosphorimager screen (Kodak).
Microarray analysis
Total bacterial RNA was purified from each sample, labelled and
hybridized to the BmG@S SAv1.1.0 microarray, as described previously.10
This array has been described elsewhere30 and contains PCR products
representing all predicted open reading frames from the initial seven
S. aureus genome sequencing projects. The array design is available
in BmG@Sbase (accession no. A-BUGS-17; http://bugs.sgul.ac.uk/
A-BUGS-17) and also ArrayExpress (accession no. A-BUGS-17). Hybridiza-
tion data were analysed using an Affymetrix 428 scanner and then quan-
tified using BlueFuse for Microarrays 3.5 software (BlueGnome). Data
analysis was performed in GeneSpring GX 7.3 (Agilent) using median-
normalized Cy5/Cy3 ratio intensities for three biological replicates. Only
genes whose expression ratio showed a ≥2-fold difference with
Benjamini and Hochberg false discovery rate ≤0.05% in the presence
of the drug were regarded as being significantly different from the
control. Fully annotated microarray data obtained using two PBD-biaryl
conjugates have been deposited in BmG@Sbase (accession no.
E-BUGS-118; http://bugs.sgul.ac.uk/E-BUGS-118) and also ArrayExpress
(accession no. E-BUGS-118).
Quantitative real-time PCR (qRT-PCR)
qRT-PCR was performed as described previously.10 The data shown are
the median of three biological and two technical replicates; each repli-
cate was performed in duplicate. Gene-specific primer pairs were
designed for genes of interest to yield amplicons of 100–150 bp and
sequences are shown in Table S3 (available as Supplementary data at
JAC Online).
Molecular modelling
Molecular modelling was employed in order to investigate the degree to
which duplex B-DNA can accommodate ELB-21 along with the degree of
distortion imparted to the B-DNA helical structure for a given sequence.
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Molecular models were constructed for the B-DNA duplexes
5′-TATAGAATCTATA-3′ and 5′-TATAGAAATCTATA-3′ (target sequence under-
lined) with and without ELB-21, forming an interstrand cross-link by
covalent binding to the two available guanine residues on opposite
strands. The AMBER31 package was used to build the initial B-DNA
structures. ELB-21, having a conformational propensity to follow the
Table 1. PBD dimers used in this study
PBD
no. Code Chemical structure
Chemical
formula
Molecular
weight
1 ELB-21 N
N
O
H
H3CO
OONH
N
O
OCH3
C35H40N4O6 612.71
2 A1 N
N
O
H
H3CO
OONH
N
O
OCH3
S S
C39H36N4O6S2 720.21
3 A2 N
N
O
H
H3CO
OONH
N
O
OCH3
C43H40N4O6 708.29
4 SG-2860
N
N
O
OMeO
H
N
ON
H
N
O
N
N
H
N
ON
H
N
OO
H
OMe
N
N
O
H
C50H56N12O10 984.07
5 SG-2891
N
HN
O
OMeO
H
N
ON
H
N
O
N
N
H
N
ON
H
N
OO
H
OMe
N
NH
O
H
SO3Na
NaO3S
C50H58N12O16Na2S2 1192
6 SG-2910
N
N
O
OMeO
H
N
O
N
HN
O
N
N
H
N
O
H
H
N
O
N
H
N
O
N
N
H
N
OO
OMe
N
N
O
H
C58H66N16O12 1179
7 SG-2242
N
NO
O
MeO
HN
H
ON
O
H
N
N
N
H
O
N
H
O
N
H
N
O
N
N
H
O
O
N
N OMe
O
H
C61H70N14O12 1191.32
8 SG-2243
N
H
NO
O
MeO
H
SO3Na
N
H
ON
O
H
N
N
O
N
H
N
H
O
N
H
N
O
N
N
H
O
OH
N
N
O
OMe
H
NaO3S C61H72N14O18Na2S2 1400
9 SG-2907
N
H
NO
O
MeO
H
SO3Na
N
H
ON
O
H
NN
N
O
N
H
N
H
O
N
N
H
N
O
N
N
H
O
OH
N
N
O
OMe
H
NaO3S C59H70N16O18Na2S2 1402
10 SG-2904
N
NO
O
MeO
HN
H
ON
O
H
N
N
O
N
H
N
N
O
H
N
H
N
O
N
NNH
O
N
H
N
O
N
N
H
O
O
OMe
N
N
O
H
C71H80N20O14 1436
11 SG-2906
N
H
NO
O
MeO
HN
H
ON
O
H
N
N
O
N
H
N
N
O
H
N
H
N
O
N
NNH
O
N
H
N
O
N
N
H
O
O
OMe
H
N
N
O
H
NaO3S
SO3Na
C71H82N20O20Na2S2 1644
12 SG-2087
N
NHN
O
MeO
H
O
N
O
N
H
OMeN
N
O
H
C33H34N7O6 624
13 SG-2088
N
N
H
N
O
MeO
H
O
N
O
H
NN
N
O
H
OMe
C33H34N7O6 624
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curve of the minor groove, was graphically aligned between the two
guanine residues using the ‘xleap’ program prior to forming a covalent
bond between the C11 of ELB-21 and C2-NH2 of each guanine. Energy
minimization was applied to the DNA without ligand using the ‘sander’
program. For the bound complex, initial minimization steps were per-
formed by application of a high positional restraint to the DNA alone,
allowing ELB-21 to adjust to the environment. To model the complex,
the DNA restraint was gradually reduced to zero in subsequent minimiza-
tion steps. After minimization, molecular dynamics simulations were
performed over 2 ns with no extra restraints applied. For the purpose of
illustration, the dynamics frame at 1 ns was saved and rendered in
each case. For all modelling, a long-range non-bonded cut-off was
applied along with use of the Generalized Born implicit solvent model
and monovalent ion screening (0.2 M). Dynamics simulations were
viewed using Visual Molecular Dynamics32 and final images rendered
with Chimera.33 PBD-biaryl conjugates were modelled in a similar way.
Results
Antibacterial and cytotoxic activity of PBD dimers
We previously examined the antibacterial activity of three PBD
dimers (SJG-136, DRG-16 and ELB-21) in which PBD units
were separated by simple three- or five-carbon methylene
chains.8 All displayed pronounced bactericidal activity against
drug-resistant Gram-positive pathogens such as MRSA and VRE
clinical isolates, with ELB-21 being the most potent of the
three. As these agents are now known to bind to a range of
sequences within duplex DNA in addition to those for which
the molecules were designed,10,17we have synthesized and eval-
uated the range of PBD dimers shown in Table 1 containing PBD
units separated by various heterocyclic moieties, in an attempt
to extend the length of the base pairs spanned between the
inter- and intrastrand cross-linked guanines and to increase
PBD dimer interactions through the choice of heterocyclic
spacers with substantial hydrogen bond donating and accepting
capabilities.
We confirmed that ELB-21 has potent inhibitory activity
against a selection of antibiotic-resistant (EMRSA-15, EMRSA-16
and BB568) and -susceptible (ATCC 29213) S. aureus strains
and, at low drug concentrations, prevented the growth of the
VRE clinical isolate VRE1 (Table 2). C2-thiophenyl substitution
(A1) of the PBD C-rings of ELB-21 made no difference to the
MIC values obtained for the Gram-positive pathogens, but the
C2-phenyl-substituted compound (A2) was less active against
drug-resistant and -susceptible strains of S. aureus (Table 2).
Pyrrole-linked PBD dimers in the compound 4–9 series
(Table 1) were designed to cross-link sites on duplex DNA of
increased length over ELB-21. These molecules have the capacity
to traverse biomembranes, as evidenced by their cytotoxicity
profile against WI38, MCF7 and A2780 cell lines, but displayed
reduced antibacterial activity in comparison with ELB-21
(Table 2). SG-2860, designed to span an 11 bp interstrand site,
possessed antibacterial activity comparable to A2; the
C11-bisulphite derivative SG-2891 yielded practically identical
MICs, indicating that slow formation of the active N10-C11
imine did not compromise the antibacterial action. Increasing
the length of the putative DNA cross-linking site by increments
from 11 bp (SG-2860) to 19 bp (SG-2906) resulted in a reduction
or abrogation of the antibacterial potency. Thus, SG-2242 was
markedly less active than SG-2860 and SG-2906 was inactive.
Antibacterial, but not cytotoxic, activity was lost when two of
the pyrroles in the SG-2242 linker were replaced with imidazole
moieties to afford SG-2907. Compounds SG-2087 and SG-2088,
in which two DC-81 type24 PBD units were linked by a single
pyrrole moiety, displayed no antibacterial activity. With the PBD
dimers examined, cytotoxic effects against cancer cell lines
Table 2. Antibacterial activity and cytotoxicity of PBD dimers
Compounda
MIC (mg/L)b IC50 (mg/L)
c
EMRSA-15 EMRSA-16 BB568 ATCC 29213 VRE1 WI38 MCF7 A2780
ELB-21 0.03 0.03 0.015 0.015 0.25 0.08–0.16 ,0.02 ,0.02
A1 0.03 0.03 0.03 0.015 0.125 ND ND ND
A2 0.125 0.125 0.25 0.125 0.125 ND ND ND
SG-2860 0.25 0.25 0.25 0.25 .16 0.08–0.16 ,0.02 ,0.02
SG-2981 0.25 0.25 0.125 0.25 .16 0.08–0.16 ,0.02 ,0.02
SG-2910 1 1 0.5 2 16 0.04–0.08 0.08–0.16 ,0.02
SG-2242 2 2 2 2 .16 0.08–0.16 0.08–0.16 ,0.02
SG-2243 2 2 2 2 8 0.08–0.16 ,0.02 ,0.02
SG-2907 16 16 8 8 .16 0.16–0.32 0.16–0.32 ,0.02
SG-2904 16 16 16 16 .16 0.16–0.32 0.08–0.16 ,0.02
SG-2906 16 .16 16 16 .16 0.16–0.32 0.32–0.65 ,0.02
SG-2087 .16 .16 .16 .16 .16 .20 5–10 ,0.02
SG-2088 .16 .16 .16 .16 .16 2.5–5 0.65–1.25 ,0.02
ND, not determined.
aStructures of PBD dimers are shown in Table 1.
bMIC for S. aureus strains EMRSA-15, EMRSA-16, BB568 and ATCC 29213, and the vancomycin-resistant enterococcal isolate VRE1.
cConcentration of PBD dimer required to kill 50% (IC50) of the population of WI38, MCF7 and A2780 cells.
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MCF7 and A2780 were greater than those found using the more
slow-growing lung fibroblast line WI38; all compounds showed a
degree of selective cytotoxicity (Table 2).
As ELB-21 was the most potent antibacterial PBD dimer
examined in this study and we have previously determined10,14
that it invoked a vigorous RecA-LexA-mediated DNA damage re-
sponse in EMRSA-16 at both sub- and suprainhibitory concentra-
tions, we employed molecular dynamics simulations (Figure 2) to
investigate the potential of the compound to produce distortions
of the DNA duplex at two drug-binding sites. Helix distortion is
known to engender ssDNA-RecA filaments that inactivate the
SOS repressor LexA and phage repressors such as Cl, resulting
in activation of the DNA damage response and derepression of
resident prophages.34,35 In the course of a dynamics simulation,
DNA undergoes a degree of conformational variability accom-
panied by periodic changes in the width of the minor groove.
Alignment of ELB-21 resulted in the C-ring (Figure 2b) of the
PBD unit oriented towards the 5′ end of the DNA strand to
which it was bound and an S-configuration at the C11 position;
a schematic of the covalent bond formed between the C11 of
the PBD unit and the guanine residue is shown in Figure S2
(available as Supplementary data at JAC Online). In the short
sequences simulated, interstrand covalent cross-links mediated
by covalent binding of ELB-21 to opposing guanine residues
restricted conformational changes and caused greater narrowing
of the minor groove by means of van der Waals interactions with
the sides of the groove compared with duplex DNA without the
drug. With the 5′-TATAGAATCTATA-3′ target sequence, it is appar-
ent that ELB-21 causes little disruption of the overall integrity of
the B-DNA helix and of the base pairing (Figure 2a and b).
Narrowing of the minor groove can also be seen where ELB-21
is bound. The model for the 5′-TATAGAAATCTATA-3′ duplex sub-
strate is considerably different (Figure 2c and d). The extra
base pair between the cross-links determines that ELB-21 is
unable to span the extended space between opposing guanines
in the natural B-DNA structure. In the course of the dynamics
simulations, the extra strain imposed by this restriction results
in distortion of the DNA, particularly in the region spanned by
the ligand, with base pairs A7-T22, A8-T21 and T9-A20 becom-
ing dislodged from their normal positions with a loss of hydrogen
bond pairing. All duplex terminal residues showed transient loss
of base pairing during the dynamics simulations. Thus, the simu-
lation indicates that ELB-21 can only be accommodated at the
expense of some conformational distortion of the DNA
(Figure 2d).
Sequence-selective binding of PBD dimers to duplex DNA
The sequence selectivity of the PBD dimers was studied by DNase
I footprinting using the HexA and HexB fragments, which
were designed to contain all 64 combinations of symmetrical
hexanucleotides.29 The reverse fragments (HexArev and
HexBrev) contain the same sequence, but in the opposite
orientation. Representative footprinting gels for the PBD dimers
are shown in Figure 3 and the general location of the footprints
is indicated in Figure S1. It is clear that the PBD dimers affect a
large number of sites on these fragments and that several of
the protected regions must consist of overlapping binding sites.
Due to the ability of these ligands to bind covalently to
guanine with high affinity, it is not possible to define the
(a) (b) (c) (d)
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T23
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A6
Figure 2. Molecular models of duplex DNA 5′-TATAGAATCTATA -3′ (a and b) and 5′-TATAGAAATCTATA-3′ (c and d) without ligand (a and c) and with
ELB-21 covalently bound to the NH2 of both guanine residues (orange) and forming an interstrand cross-link (b and d). The structures are frames
from dynamics simulations after 1 ns. Bases are enumerated beginning at the 5′ end of one strand and continuing from the 5′ end of the
opposing strand. The schematics show a ribbon running through the DNA backbone and slab bases are shown in blue, except for guanines, in
orange. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.
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Figure 3. DNase I footprints showing the interaction of the PBD dimers with HexA and HexB fragments. The sequences of these fragments are shown
in Figure S1. Concentrations of the ligand (mM) are indicated at the top of each gel lane. Tracks labelled ‘con’ show DNase I cleavage in the absence of
added ligand, while ‘GA’ tracks are markers specific for purines (G+A). (a) HexAfor and HexArev. (b) HexBfor and HexBrev. The DNA fragments were
labelled at their 3′-ends with 32P.
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precise binding preference of each ligand, though some general
features can be determined. In general, the size of the footprints
correlated with the length of the linkers separating the two PBD
monomeric units, with larger footprints observed with longer
linkers. Similarly, the sodium bisulphite salt form of the PBD
dimers and their corresponding imine forms (e.g. SG-2860 and
SG-2891, and SG-2242 and SG-2243) provided identical footprint
patterns in terms of footprint lengths and location. This observa-
tion is expected, as the bisulphate forms are considered as the
pro-drug of the corresponding imine form of PBD dimers and
are expected to hydrolyse to generate the imine form under
experimental conditions.36
The length of the footprints observed for these compounds
ranged from short regions of protection of 3–7 bases to very
large footprints spanning 38 bp that contain at least seven po-
tential binding sites (Figure S1). This range of sequence protec-
tion can be explained by the suggestion that the reactive imine
moiety of PBDs is able to covalently attach to the guanine of
every X-G-X binding site, and the presence of a large number
of such potential binding sites within a long DNA fragment
results in the complete inhibition of DNase I cleavage. A detailed
analysis of the footprinting sites revealed protection at sequences
that correspond to both inter- and intrastrand cross-links
(e.g. intrastrand 5′-GTACTAG-3′, 5′-GCTATAG-3′, 5′-GATATATG-3′,
5′-GCTTAAG-3′ and 5′-GCTTATAAG-3′, and interstrand 5′-
GTTTAAAC-3′, 5′-GTTAAC-3′, 5′-GTATAC-3′ and 5′-GTATATAC-3′)
and monoalkylating sites (e.g. 5′-GCCAAATTTA-3′), which is in
agreement with the type of adducts reported previously.17
However, due to the complex and relatively large nature of
these footprints, it was not possible to assign specific protection
sequences to individual molecules, though it should be noted
that although they have many protected regions in common,
the detailed patterns are not the same for each ligand.
Antibacterial and cytotoxic activity of PBD-biaryl
conjugates
Each of the 43 members of the PBD-biaryl conjugate library was
examined for its capacity to inhibit the growth of four MRSA clin-
ical isolates (EMRSA-15, EMRSA-16, BB568 and USA300), one
vancomycin-intermediate resistant MRSA (Mu50) and two VRE
isolates (VRE1 and VRE10). MIC values obtained for these bac-
teria are shown in tabular form in Table S4 (available as Supple-
mentary data at JAC Online). With one exception, the MICs
obtained for the seven Gram-positive strains of any one
compound were comparable; the antibacterial activities of the
compounds are therefore categorized in grid form in Figure 4
as effective (bacteria susceptible; ≤4 mg/L), partially effective
(8–16 mg/L) or ineffective (≥32 mg/L). Twenty-six compounds
produced MIC values of ≤4 mg/L for all test strains. Some
were highly potent, e.g. 35 (BztMC-Im-PBD; BztMC¼methyl
5-aminobenzothiophene-2-carboxylate) and 36 (MPB-Im-PBD)
produced MICs of 0.06 mg/L for all strains tested and sub-mg/L
values were obtained with a further 12 compounds. In the
large majority of cases, activities against staphylococci and
streptococci were comparable. In one case (59;
Py-Py-Py-Py-MPB-PBD; Py¼1-methylpyrrol-3-amine), a broad
range of intermediate susceptibility values against the various
strains was found. Fourteen compounds possessed no detect-
able antibacterial activity.
The PBD-biaryl conjugates have been developed as a series of
linear molecules in which combinations of the various
In-PBD (14) MEB-PBD (23) MPA-Py-PBD (31) MPA-Im-PBD (40) FB-MPB-PBD (48) Py-Py-MPB-PBD (57) 
Bzt-PBD (15) Py-Py-PBD (24) PyM-Im-PBD (32) Py-MPB-PBD (41) MB-MPB-PBD (49) Py-Im-MPB-PBD (58) 
MPB-PBD (16) In-Py-PBD (25) Im-Im-PBD (33) PyM-MPB-PBD (42) MEB-MPB-PBD (51) Py-Py-Py-Py-MPB-PBD (59)
FB-PBD (17) Bzf-Py-PBD (26) In-Im-PBD (34) Im-MPB-PBD (43) MEPM-MPB-PBD (52)
TB-PBD (18) Bzt-Py-PBD (27) BztMC-Im-PBD (35) In-MPB-MPD (44) MPA-MPB-PBD (53)
MtaB-PBD (19) BztMC-Py-PBD (28) MPB-Im-PBD (36) Bzt-MPB-PBD (45) Py-FB-PBD (54)
TdB-PBD (20) MPB-Py-PBD (29) MB-Im-PBD (37) BztMC-MPB-PBD (46) In-FB-PBD (55)
MMB-PBD (22) MB-Py-PBD (30) MEB-Im-PBD (39) MPB-MPB-PBD (47) MPB-FB-PBD (56)
8–16 mg/L ≥32 mg/L£4 mg/L
Figure 4. Antibacterial activity (MICs) of PBD-biaryl conjugates as determined using five staphylococcal and two enterococcal clinical
isolates. Compounds eliciting MIC values of ≤4 mg/L for all seven Gram-positive bacteria were considered effective. The numbering system
for the components of the compound library is shown in Table S1. PBD, pyrrolo(2,1-c)(1,4)benzodiazepine; Py, 1-methylpyrrol-3-amine; PyM,
(1,5-dimethylpyrrol-2-yl)methanamine; Im, 1-methylimidazol-4-amine; In, 1-methylindol-5-amine; Bzf, benzofuran-5-amine; Bzt, benzothiophen-5-
amine; BztMC, methyl 5-aminobenzothiophene-2-carboxylate; MPB, 4-(1-methyl-1H-pyrrol-3-yl)benzenamine; FB, 4-(3-furyl)benzenamine; TB,
4-(3-thienyl)benzenamine; MTaB, 3-(2-methylthiazol-4-yl)benzenamine; TdB, 4-(thiadiazol-4-yl)benzenamine; MB, 4-morpholinobenzenamine;
MPpB, 4-(4-methylpiperazin-1-yl)benzenamine; MMB, 4-(morpholinomethyl)benzenamine; MEB, 4-(2-morpholinoethoxy)benzenamine; MEPM,
[4-(2-morpholinoethoxy)phenyl]methanamine; MPA, 6-morpholinopyridin-3-amine.
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heterocyclic building blocks have been incorporated in order to
optimize, through their unique curvature, the number of van
der Waals contacts within G:C tracts of the DNA minor groove.
The sequence of the units incorporated into conjugates influ-
ences potency, e.g. utilizing 4-(3-furyl)benzenamine (FB), MPB
and PBD in the configuration MPB-FB-PBD produces the highly
active (MIC¼0.5 mg/L) molecule 56, but the FB-MPB-PBD ar-
rangement 48 is inactive (≥32 mg/L). Similarly, the activity of
conjugates containing Im, MPB and PBD is increased .30-fold
when the order of these moieties is changed from Im-MPB-PBD
(43) to MPB-Im-PBD (36). This trend was also evident with the
Py-containing conjugates Py-MPB-PBD (41; MIC¼1 mg/L) and
MPB-Py-PBD (29; 0.125 mg/L). All conjugates containing 1-
methylindol-5-amine (In) were inactive, regardless of the pres-
ence of other moieties (e.g. compounds 14, 25, 34, 44 and 55).
In some instances, the introduction of an MPB unit between
another heterocycle and PBD resulted in a loss of antibacterial
activity: benzothiophen-5-amine (Bzt)-PBD (15) possessed MICs
of 0.25–2 mg/L and Bzt-Py-PBD (27) yielded some of the lowest
MICs in this study, but Bzt-MPB-PBD (45) was inactive; FB-PBD is
potent (17; 0.125–1 mg/L), but, as noted above, FB-MPB-PBD is
inactive. However, substitution of the non-terminal Py heterocycle
in Py-Py-PBD (24) to yield Py-MPB-PBD (41) made little difference
to the bioactivity of this type of conjugate. In a number of
instances, activity was significantly increased by the introduction
of units between the heterocycle and the PBD unit, particularly in
two-component conjugates. For example, the antibacterial activ-
ities of 4-(2-morpholinoethoxy)benzenamine (MEB)-Im-PBD (39;
0.25 mg/L) and MEB-MPB-PBD (51; 2 mg/L) contrasted with the
lack of activity of MEB-PBD (23).
Mode of killing of EMRSA-16 by PBD-biaryl conjugates
The effect of the highly-active PBD-biaryl conjugates 28, 29, 36
and 57 on the viability of EMRSA-16 was determined.
Mid-logarithmic-phase bacteria were exposed to a range of
drug concentrations (0.5× MIC, 1× MIC, 2× MIC and 4× MIC),
and the cell density (OD600) and viability (cfu/mL) determined
at various times during incubation with agitation (200 rpm) at
378C. Compounds 29, 36 and 57 exhibited potent bactericidal
activity at suprainhibitory concentrations; 28 elicited relatively
weak killing activity (2–3 log reduction in viable count) only at
the highest concentration used (Figure 5). With all four com-
pounds, there were increases in EMRSA-16 viability over the
24 h incubation period following the reductions that occurred
over the initial 8 h (Figure 5). This regrowth was not due to the
emergence of resistant phenotypes, as MIC values obtained for
bacteria recovered from the 24 h cultures were identical to
those for the inoculum.
ELB-21 and other PBD dimers produce similar bactericidal
effects with EMRSA-16 and other S. aureus strains,8,10 and
appear to act above the MIC threshold by damaging DNA to
such an extent that it cannot be repaired by the bacterial
RecA-LexA-mediated SOS response system;14 these compounds
also induce genes associated with the staphylococcal patho-
genicity island SaPI4 and prophage genes, resulting in the
release of viable phage from treated cells.10,14 We therefore
examined the gene transcriptional response of EMRSA-16 to
the mono-adduct-forming PBD-biaryl conjugates 28 and 57 to
determine if these compounds elicit similar effects. There was
a significant ≥2-fold change in the expression of 174 genes
following the exposure of logarithmic-phase bacteria to subinhi-
bitory concentrations (0.5×MIC) of the potent bactericidal conju-
gate 57; 120 genes were up-regulated and 102 of these were
genes associated with resident S. aureus prophages wSa2 and
wSa3.37 Lists of up- and down-regulated genes are shown in
Tables S5 and S6 (both available as Supplementary data at JAC
Online), and the complete data set can be found in ArrayExpress
(accession no. E-BUGS-118). Five genes involved in DNA damage
repair, including uvrA (encoding excinuclease ABC subunit A),
uvrB (excinuclease ABC subunit B), gyrA (DNA gyrase subunit A)
and rir2 (ribonucleoside-diphosphate reductase b chain), were
up-regulated, as were three genes encoding cell wall turnover
proteins. Fifty-four genes showed reduced expression following
exposure to 57; a high proportion was involved in membrane
transport and bioenergetics, capsular polysaccharide synthesis,
protein synthesis and protein modification. Fewer genes were
modulated by subinhibitory concentrations of the less overtly
bactericidal compound 28, with a total of 91 genes up-regulated
≥2-fold; there was no significant inhibition of gene expression. All
genes up-regulated by 28 were also up-regulated by compound
57, but in general to a lesser degree. Changes in the expression
of nine genes in logarithmic-phase cultures of EMRSA-16 follow-
ing exposure to conjugates 28 and 57 were validated using
qRT-PCR; genes with varying degrees of modulation of expression
were selected (Table 3). Pearson correlation coefficient analysis
demonstrated a significant correlation (P≤0.0001, two-tailed)
and an R2 value of 0.9537, equivalent to a 95.37% correlation
between the two methods of assessment of gene expression.
Models of energy-minimized interactions between consensus
nucleotide sequences10 and both the most potent bactericidal
agent MPB-Im-PBD (36) and the markedly less active Py-Py-
PBD (24) indicated that these molecules cause less distortion
of the DNA helix compared with members of the PBD dimer
series; modelling suggested that the more potent compound
36 may produce little or no distortion of the helix (Figure 6).
Calculation of the free energy of binding showed that 36 is
favoured over 24 (a difference of 15 kcal/mol).
Discussion
The capacity of PBD dimers in which the PBD monomers are
separated by short C8/C8′ diether linkages containing odd
numbers of methylenes (n¼3 or 5; Figure 1) to form interstrand
and intrastrand cross-linked adducts and monoalkylated
adducts with duplex DNA by virtue of covalent aminal linkages
with guanine C2-NH2 functionalities has been thoroughly charac-
terized.12,17,22 The type and distribution of these adducts is de-
pendent on the length of the linker and the positioning of two
reactive guanine bases on the same or opposite strands, and
their separation by intervening base pairs.38 The available evi-
dence strongly suggests that both the cytotoxic39,40 and antibac-
terial activities10,14 of such PBD dimers are dependent on these
covalent interactions with DNA. Indeed, interstrand cross-links
induced by SJG-136 have been demonstrated in peripheral
blood lymphocytes during clinical trials of this agent.41 ELB-21
elicits potent antibacterial activity that is restricted to Gram-
positive species, many of current medical importance. We
identified and validated a large number of interstrand and
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Figure 5. Response of EMRSA-16 to subinhibitory and suprainhibitory concentrations of compounds 57 (a and b), 28 (c and d), 29 (e and f) and 36
(g and h). Compounds were added to mid-logarithmic-phase cultures (OD6000.1; 3 h), OD600 measured (a, c, e and g) and viable numbers
determined (b, d, f and h): filled circles, no drug; open circles, 0.5× MIC; filled triangles, 1× MIC; open triangles, 2× MIC; and filled squares, 4× MIC.
Error bars represent+1 SD; n¼3.
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intrastrand ELB-21 binding sequences within the genome of
S. aureus (40000) that probably account for the MICs of
0.015–0.03 mg/L for the staphylococcal strains shown in
Table 2. This compound and other structurally related agents
(Figure 1) display significant cytotoxicity against human cell
lines,15,16 although this has not precluded the promotion of
SJG-136 to human Phase II evaluation in ovarian cancer and leu-
kaemia with an excellent safety profile.42 We sought to restrict
the cytotoxicity of antibacterial PBD dimers through targeting
of extended DNA binding sites, which appear less frequently
within the staphylococcal and human genomes, by increasing
the length of the linker region; we also examined the antibacter-
ial activity of ELB-21 analogues through modification of the
PBD units.
Increasing the molecular distance between the two PBD units
in the PBD dimer series shown in Table 1 led to a progressive re-
duction in antibacterial activity against the five Gram-positive
strains examined, even though, generally, the compounds
retained their cytotoxic capacity (Table 2). Dimers in the
SG-2860–2906 numerical series were significantly less potent
against all strains tested compared with ELB-21 and showed
strong if complex patterns of binding to duplex DNA, as evi-
denced by DNase I footprinting (Figures 3 and S1), indicating
that the relatively weak antibacterial activity was most likely
due to a lack of capacity to traverse the cell wall and/or cytoplas-
mic membrane of the staphylococcal and enterococcal targets.
Two compounds, SG-2087 and SG-2088, possessed no discern-
ible antibacterial activity and produced no significant DNA foot-
prints at the highest drug concentrations used, indicating that
the presence of PBD units within PBD dimers is not a prerequisite
for antibacterial activity through DNA cross-linking. Thus, ELB-21
remains the most potent PBD dimer with respect to activity
against Gram-positive pathogens and no improvement in its
potency could be elicited by functionalizing the C-ring of the
PBD units in the manner described earlier (Table 2). The in vitro
cytotoxicity and bioactivity of SJG-136 and ELB-21 are similar.
SJG-136 is progressing through the clinic for cancer indications
and has been found to be relatively well tolerated in human sub-
jects42 in comparison with other cytotoxic drugs; ELB-21 may
have the potential, therefore, for clinical use as a ‘drug of last
resort’ against intractable, life-threatening infections caused by
MRSA, VRE and other dangerous Gram-positive pathogens.
However, we have also focused in this study on a new generation
of PBD-based DNA-interactive molecules, PBD-biaryl conjugates.
Representatives of this class are remarkably well tolerated in
mice at high concentrations (D. E. Thurston, unpublished obser-
vations) and we therefore expected them to yield a more favour-
able toxicity profile than PBD dimers such as ELB-21 when
evaluated as antibacterial agents.
A high proportion (26 from 43) of compounds from the library
detailed in Figure 4 and Table S1 yielded MICs of ≤4 mg/L, and
many of these were effective at ,1 mg/L (Table S4). Six com-
pounds were particularly potent against the MRSA/VRE panel
and their structures are shown in Figure 7. It is our intention to
select one or two of these agents for further profiling and for
preclinical and, potentially, clinical evaluation. Interestingly,
Table 3. Comparison of microarray and qRT-PCR data following
exposure of EMRSA-16 to PBD-biaryl conjugates 28 and 57 at
concentrations of 0.5×MIC
Gene Compound Microarray qRT-PCRa
grlA 57 1.03 0.75
28 1.14 1.37
grlB 57 0.92 1.57
28 1.05 1.54
gyrA 57 3.44* 4.20**
28 1.10 1.11
gyrB 57 3.63 7.79**
28 1.03 1.49
samB 57 17.25* 128.41**
28 5.34* 28.28**
uvrA 57 2.95* 4.97**
28 2.17* 2.91**
uvrB 57 3.55* 7.83**
28 2.38* 3.95**
cap5L 57 0.28* 0.11**
28 0.60 0.80
mnhD 57 0.35* 0.23**
28 0.91 0.75
amRNA expression levels were normalized to 16S rRNA.
*P,0.05.
**P,0.001.
Figure 6. In silico energy-minimized structures of the PBD binding target
sequence TATAGAATCTATA and compound 24 Py-Py-PBD (left) and
compound 36 MPB-Im-PBD (right). The covalent binding site is shown
in orange. This figure appears in colour in the online version of JAC and
in black and white in the print version of JAC.
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as these compounds possessed between two and nine orders of
magnitude less cytotoxicity against non-proliferating as com-
pared with proliferating human cell lines, we exposed 24 h
TUPLF/AB zebrafish (Danio rerio) embryos to these six conjugates,
monitoring viability and morphology over a 5 day period; we
found no evidence of toxicity when concentrations up to
20-fold MIC were employed (J. B. Moreira and P. W. Taylor,
unpublished observations). The PBD-biaryl conjugates were
designed to preferentially bind to G:C-rich sequences. We have
shown by fluorescence resonance energy transfer-based
thermal denaturation that they stabilize G:C-rich sequences up
to 13-fold compared with A:T-rich sequences and by ion-pair
HPLC-MS that the MPB units in compounds such as 29, 36 and
57 (Figure 7) prefer G:C base pairs close to the PBD covalent at-
tachment site. DNase I footprinting demonstrated strong binding
in G:C-rich regions that varied consistently in relation to the
relative position of the building block within the molecule
(K. M. Rahman, K. R. Fox and D. E. Thurston, unpublished observa-
tions). Molecular dynamics simulations with MPB-containing
PBD-biaryl conjugates indicate that these molecules are more
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Figure 7. Structures of PBD-biaryl conjugates with potent activity (0.06 mg/L) against a panel of Gram-positive pathogens. The structures
for BztMC-Im-PBD (35), BztMC-Py-PBD (27), Bzf-Py-PBD (26), Py-Py-MPB-PBD (57), MPB-Py-PBD (29) and MPB-Im-PBD (36) have been extracted
from Table S1.
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easily accommodated within the minor groove than PBD dimers
such as ELB-21 and cause less distortion to the DNA duplex
(compare Figure 6 with Figure 2). It is important, however, that
the outcomes of these simulations be verified by experimental
observation.
Some clear relationships emerged from comparison of the
PBD-biaryl structures and their antibacterial activity: (i) the
potency is highly influenced by the positions of the incorporated
units; (ii) all In-containing conjugates are inactive; (iii) a single
MPB unit is essential for enhanced activity (e.g. PBD-Im-Im had
only weak activity of 4–16 mg/L and a PBD-MPB-MPB conjugate
was inactive against both MRSA and VRE, but PBD-Py-MPB and
PBD-Im-MPB were highly active with MICs of 0.06 mg/L); (iv) a
five-membered heterocycle between the MPB and PBD units pro-
vides optimum activity; (v) switching the position of the MPB
unit (e.g. PBD-MPB-Im in place of PBD-Im-MPB) reduces activity
by 16–32-fold; (vi) introduction of a second five-membered
heterocycle after MPB increases potency by 10–50-fold
(PBD-MPB-Im-Py compared with PBD-MPB-Py); and (vii) more
than two heterocycles after the MPB reduces potency. These pre-
liminary data underline the potential of the strongly bioactive
PBD-biaryl conjugates as prototypical agents for the treatment
of systemic Gram-positive infections.
The limited acute toxicity data currently available for
PBD-biaryl compounds (D. E. Thurston, unpublished observations)
indicate that their therapeutic index is likely to be superior to that
for PBD dimers and our future efforts to develop PBD conjugates
as antibacterial chemotherapeutics for multidrug-resistant
Gram-positive pathogens will therefore focus on these agents.
Molecular dynamics simulations suggest that PBD-biaryl com-
pound 36 (MPB-Im-PBD) causes virtually no distortion of the
DNA duplex following binding to the target guanine within the
minor groove, even though this conjugate possesses potent anti-
bacterial activity. If this a general feature of bioactive PBD-biaryl
conjugates, it is likely to impact advantageously on the safety
profile. Conformational distortion is known to engender activa-
tion of the bacterial DNA damage response;34,35 transcriptomic
analysis of gene expression following exposure of EMRSA-16 to
28 and 57 strongly suggests that, similar to ELB-21,10,14 the bac-
tericidal effects are due to the failure of the target bacteria to
excise and repair regions of DNA to which conjugates are cova-
lently attached. Less pronounced induction of the RecA-LexA
response by PBD-biaryl conjugates in comparison with ELB-21
probably reflects a lack of helix distortion following covalent at-
tachment of the drug. Similarly to ELB-21,10,14 PBD-biaryl conju-
gates also engendered activation of prophage genes within the
EMRSA-16 genome.
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